A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

LESSONS LEARNED: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy. Adverse events with fulvestrant maintenance therapy were co...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, Wang, Shusen
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2020
Onderwerpen:
Clinical Trial Results
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100565/
https://ncbi.nlm.nih.gov/pubmed/33245164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13614
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items